VIENNA – Interim phase IIa data of hepatitis B core protein inhibitor ABI-H0731, from Assembly Biosciences Inc., used in combination with nucleos(t)ide (Nuc) analogues, indicate deep declines of hepatitis B virus (HBV) RNA and DNA to significantly low levels, suggesting potentially curative abilities.